超声影像组学预测三阴性乳腺癌无病生存期的多中心研究
该多中心研究纳入486例三阴性乳腺癌患者,基于治疗前灰阶超声提取肿瘤及瘤周影像组学特征构建组学标签与列线图,整合临床病理变量预测无病生存期。组学列线图在训练集、内部验证集和外部验证集的C-index分别为0.75、0.73和0.71,优于临床病理模型和TNM分期,校准曲线显示预测生存一致性良好。
要点
- 治疗前灰阶超声影像组学特征可对三阴性乳腺癌患者进行复发风险分层。
- 整合影像组学标签与临床病理变量的列线图预测无病生存期优于TNM分期。
- 高Rad-score提示预后更差,组学列线图在内外验证中均保持较好区分度。
核心结论
- 基于治疗前灰阶超声的影像组学标签是三阴性乳腺癌患者风险分层的潜在生物标志物。
- 整合影像组学特征与临床数据的列线图能较准确预测个体复发风险,优于临床病理模型和TNM分期。
研究设计与样本
- 多中心回顾性研究,连续纳入3家机构共486例三阴性乳腺癌患者,分为主要队列216例、内部验证队列108例和外部验证队列162例。
- 从治疗前灰阶超声图像的肿瘤及瘤周区域提取影像组学特征,采用LASSO逻辑回归筛选复发相关特征并构建组学标签。
- 采用单因素和多因素Cox回归整合独立临床病理变量与组学标签建立列线图,在内部和外部队列中验证区分度、校准度和临床实用性。
关键影像表现/征象
- 在主要队列和两个验证队列中,Rad-score较高的患者预后结局均差于Rad-score较低者(所有p < 0.05)。
诊断标准与关键数值
- 影像组学列线图训练C-index为0.75(95%CI 0.71-0.80),内部验证C-index为0.73(95%CI 0.69-0.78),外部验证C-index为0.71(95%CI 0.66-0.76)。
- 影像组学列线图预后性能优于临床病理模型和肿瘤淋巴结转移分期系统(p < 0.01)。
- 校准曲线显示影像组学模型对生存预测具有良好一致性。
临床应用与阅片要点
- 可基于治疗前灰阶超声提取肿瘤及瘤周影像组学特征,结合临床病理变量评估三阴性乳腺癌患者无病生存期风险。
- 高Rad-score提示复发风险较高,阅片时可关注相应影像组学特征对应的图像区域。
- 影像组学列线图可作为TNM分期之外的补充工具,辅助个体化预后评估和治疗决策。
局限性
- 研究为回顾性设计,可能存在选择偏倚。
- 外部验证虽独立但与开发队列同属多中心研究框架,泛化性仍需更广泛人群验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To explore the predictive value of radiomics nomogram using pretreatment ultrasound for disease-free survival (DFS) after resection of triple negative breast cancer (TNBC).
METHODS AND MATERIALS: A total of 486 TNBC patients from 3 different institutions were consecutively recruited for this study. They were categorized into the primary cohort (n = 216), as well as the internal validation cohort (n = 108) and external validation cohort (n = 162). In primary cohort, least absolute shrinkage and selection operator logistic regression algorithm was used to select recurrence-related radiomics features extracted from the breast tumor and peritumor regions, and a radiomics signature was constructed derived from the grayscale ultrasound images. A radiomic nomogram integrating independent clinicopathological variables and radiomic signature was established with uni- and multivariate cox regressions. The predictive nomogram was validated using an internal cohort and an independent external cohort regarding abilities of discrimination, calibration and clinical usefulness.
RESULTS: The patients with higher Rad-score had a worse prognostic outcome than those with lower Rad-score in primary cohort and two validation cohorts (All p < 0.05).The radiomics nomogram indicated more effective prognostic performance compared with the clinicopathological model and tumor node metastasis staging system (p < 0.01), with a training C-index of 0.75 (95% confidence interval (CI), 0.71-0.80), an internal validation C-index of 0.73 (95% CI, 0.69-0.78) and an external validation 0.71 (95% CI,0.66-0.76). Moreover, the calibration curves revealed a good consistency for survival prediction of the radiomics model.
CONCLUSIONS: The ultrasound-based radiomics signature was a promising biomarker for risk stratification for TNBC patients. Furthermore, the proposed radiomics modal integrating the optimal radiomics features and clinical data provided individual relapse risk accurately.
ADVANCES IN KNOWLEDGE: The radiomics model integrating radiomic signature and independent clinicopathological variables could improve individual prognostic evaluation and facilitate therapeutic decision-making, which demonstrated the incremental value of the radiomics signature for prognostic prediction in TNBC.
引用
- Yu F, Hang J, Deng J, et al. Radiomics features on ultrasound imaging for the prediction of disease-free survival in triple negative breast cancer: a multi-institutional study. Br J Radiol. 2021. PMID: 34478336. doi:10.1259/bjr.20210188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。